EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-Derived Organoid Modeling of Glypican-3 CAR-T Responses in Hepatocellular Carcinoma

Bohan Zhang, Yun Deng, Mingshan Zhou iD, Junfei Chen, Jiawen Wu, Xiaofeng Lian, Miaoxin Zhu, Min Zhou, Jie Cao

Cells · 28.04.2026 · 15 (9) · 799

DOI: 10.3390/cells15090799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 28.04.2026. Verfasst von Bohan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Organoids, Glypicans. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the State Key Laboratory of Systems Medicine for Cancer, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glypican-3 (GPC3)-targeted chimeric antigen receptor T (CAR-T) cell therapy is a promising approach for hepatocellular carcinoma (HCC), but marked interpatient variability and antigen heterogeneity limit its broader application. Here, we established a patient-derived organoid (PDO)-based platform to functionally evaluate autologous GPC3-targeted CAR-T cell activity in HCC. HCC PDOs preserved key histologic features and heterogeneous GPC3 expression patterns of the original tumors. In co-culture assays, CAR-T cell cytotoxicity was associated with GPC3 expression levels and was accompanied by IFN-γ and IL-2 release, supporting the feasibility of using PDOs for functional assessment of CAR-T cell sensitivity. We further found that matrix conditions strongly influenced organoid architecture, viral transduction, CAR-T cell infiltration, and killing efficiency, with lower Matrigel concentrations providing a more permissive setting for functional assessment. Importantly, in GPC3-low PDOs, pretreatment with the DNA methyltransferase inhibitor 5-azacytidine (5-AZA) reduced DNA methyltransferase 3 alpha (DNMT3A) expression, increased surface GPC3 expression, and significantly enhanced CAR-T-mediated cytotoxicity. Together, these findings provide proof-of-concept evidence supporting the use of HCC PDOs as a patient-derived platform for modeling selected determinants of GPC3-targeted CAR-T cell activity and for exploring combination strategies to improve therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsOrganoidsGlypicansReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansCell Line, Tumor

Stichwörter der Autor:innen

chimeric antigen receptor T cellglypican-3hepatocellular carcinomapatient-derived organoids

Substanzen

GlypicansReceptors, Chimeric AntigenGPC3 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China.
  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
  • Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Shanghai 200127, China.

ORCID-Profile: Mingshan Zhou

Förderung

  • the National Natural Science Foundation of China
  • the State Key Laboratory of Systems Medicine for Cancer
  • National Natural Science Foundation of China
  • State Key Laboratory of Systems Medicine for Cancer

Zitieren

APA

Zhang, B., Deng, Y., Zhou, M., Chen, J., Wu, J., Lian, X., Zhu, M., Zhou, M., & Cao, J. (2026). Patient-Derived Organoid Modeling of Glypican-3 CAR-T Responses in Hepatocellular Carcinoma. Cells, 15(9), 799. https://doi.org/10.3390/cells15090799

Vancouver

Zhang B, Deng Y, Zhou M, Chen J, Wu J, Lian X, et al. Patient-Derived Organoid Modeling of Glypican-3 CAR-T Responses in Hepatocellular Carcinoma. Cells. 2026;15(9):799. doi:10.3390/cells15090799

BibTeX
@article{Zhang2026,
  author = {Zhang, Bohan and Deng, Yun and Zhou, Mingshan and Chen, Junfei and Wu, Jiawen and Lian, Xiaofeng and Zhu, Miaoxin and Zhou, Min and Cao, Jie},
  title = {Patient-Derived Organoid Modeling of Glypican-3 CAR-T Responses in Hepatocellular Carcinoma},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {799},
  doi = {10.3390/cells15090799}
}
Kostenlos starten →